Comparison of NSCLC patient groups with activated EGFR
mutations treated with three different tyrosine-kinase
inhibitors (TKI): Real-life data from the Czech Republic

a 2017

Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic

SKŘIČKOVÁ, Jana; Renata CHLOUPKOVÁ; Karel HEJDUK; Miloš PEŠEK; Vítězslav KOLEK et. al.

Základní údaje

Originální název

Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic

Autoři

Vydání

ERS international Congress 2017, 2017

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30203 Respiratory systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 12.244

Kód RIV

RIV/00216224:14110/17:00098882

Organizační jednotka

Lékařská fakulta

ISSN

Klíčová slova anglicky

NSCLC

Štítky

EL OK

Změněno: 16. 3. 2018 15:20, Soňa Böhmová

Anotace

V originále

Background and Aim: From October 2013 there is a possibility to treat patients with NSCLC and with activated epidermal growth factor receptor (EGFR) mutations with three TKI (afatinib, eriotinib, gefitinib) in the Czech Republic. We have tried to find differences among patient groups treated with single TKI in 1st line of treatment. Patients and methods: As data source we used the TULUNG registry, which is focused on the data collection of patients with NSCLC treated with target therapy in the Czech Republic. We analysed 232 patients (gefitinib - 115 patients, afatinib - 77 patients, eriotinib - 40 patients.). Statistical significance was assessed using the Fisher's exact test or Kruskal-Wallis test (a=0.05).

Citovat

SKŘIČKOVÁ, Jana; Renata CHLOUPKOVÁ; Karel HEJDUK; Miloš PEŠEK; Vítězslav KOLEK; Leona KOUBKOVÁ; Jaromír ROUBEC; Markéta ČERNOVSKÁ; František SALAJKA; Jana KREJČÍ; Libor HAVEL; Marcela TOMÍŠKOVÁ; Monika ŠATÁNKOVÁ; Andrea BENEJOVÁ; Ivona GRYGÁRKOVÁ; Michal HRNČIARIK; Milada ZEMANOVÁ; Dimka SIXTOVÁ a Zdeněk MERTA. Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic. In ERS international Congress 2017. 2017. ISSN 0903-1936.

@proceedings{1400030,
   author = {Skřičková, Jana and Chloupková, Renata and Hejduk, Karel and Pešek, Miloš and Kolek, Vítězslav and Koubková, Leona and Roubec, Jaromír and Černovská, Markéta and Salajka, František and Krejčí, Jana and Havel, Libor and Tomíšková, Marcela and Šatánková, Monika and Benejová, Andrea and Grygárková, Ivona and Hrnčiarik, Michal and Zemanová, Milada and Sixtová, Dimka and Merta, Zdeněk},
   booktitle = {ERS international Congress 2017},
   keywords = {NSCLC},
   language = {eng},
   title = {Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic},
   year = {2017}
}

TY  - CONF
ID  - 1400030
AU  - Skřičková, Jana - Chloupková, Renata - Hejduk, Karel - Pešek, Miloš - Kolek, Vítězslav - Koubková, Leona - Roubec, Jaromír - Černovská, Markéta - Salajka, František - Krejčí, Jana - Havel, Libor - Tomíšková, Marcela - Šatánková, Monika - Benejová, Andrea - Grygárková, Ivona - Hrnčiarik, Michal - Zemanová, Milada - Sixtová, Dimka - Merta, Zdeněk
PY  - 2017
TI  - Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic
KW  - NSCLC
N2  - Background and Aim: From October 2013 there is a possibility to treat patients with NSCLC and with activated epidermal growth factor receptor (EGFR) mutations with three TKI (afatinib, eriotinib, gefitinib) in the Czech Republic. We have tried to find differences among patient groups treated with single TKI in 1st line of treatment. Patients and methods: As data source we used the TULUNG registry, which is focused on the data collection of patients with NSCLC treated with target therapy in the Czech Republic. We analysed 232 patients (gefitinib - 115 patients, afatinib - 77 patients, eriotinib - 40 patients.). Statistical significance was assessed using the Fisher's exact test or Kruskal-Wallis test (a=0.05).
ER  -

SKŘIČKOVÁ, Jana; Renata CHLOUPKOVÁ; Karel HEJDUK; Miloš PEŠEK; Vítězslav KOLEK; Leona KOUBKOVÁ; Jaromír ROUBEC; Markéta ČERNOVSKÁ; František SALAJKA; Jana KREJČÍ; Libor HAVEL; Marcela TOMÍŠKOVÁ; Monika ŠATÁNKOVÁ; Andrea BENEJOVÁ; Ivona GRYGÁRKOVÁ; Michal HRNČIARIK; Milada ZEMANOVÁ; Dimka SIXTOVÁ a Zdeněk MERTA. Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic. In \textit{ERS international Congress 2017}. 2017. ISSN~0903-1936.

Přehled o publikaci